Case Report

Using Etomidate in a 2-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma

10.4274/jcrpe.galenos.2020.2020.0164

  • Ahreum Kwon
  • Yongha Choi
  • Jo Won Jung
  • Junghwan Suh
  • Ho-Seong Kim

Received Date: 14.07.2020 Accepted Date: 28.10.2020 J Clin Res Pediatr Endocrinol 0;0(0):0-0 [e-Pub] PMID: 33251784

Cushing syndrome (CS) is a rare disease caused by hypercortisolemia. Although surgical treatment is first-line treatment in CS, the appropriate medication for the patient’s condition should be selected when medical treatment is needed. Etomidate is an adrenal-blocking drug used to treat CS and the most suitable for severe hypercortisolemia and adrenocortical carcinoma (ACC), due to cardiovascular stability and anti-tumorigenic effect. However, its use and safe recommended dosage in infants with CS is unreported. Here we describe the case of a 2-month-old girl treated with etomidate for CS caused by ACC. Even though radical mass excision was performed, severe hypercortisolemia persisted, resulting from metastatic lesions in the liver, and medical treatment was considered. The etomidate doses, no bolus dose and infusion rate of 0.03 mg/kg/hour, may be appropriate dose for severe hypercortisolemia in infants. This case will help determine future treatment strategies for similar cases in infants.

Keywords: etomidate, infant, Cushing syndrome